Presentations

    Systems toxicology assessment of a representative e-liquid formulation by using human primary bronchial epithelial cells

    Marescotti, D.

    Conference date
    Sep 24, 2020
    Conference name
    3rd Scientific Summit on Tobacco Harm Reduction: Novel producs, Research & Policy 2020
    Topic
    Summary

    Our scientists presented at the 3rd Scientific Summit on Tobacco Harm Reduction: Novel products, Research & Policy on September 24, 2020 by pre-recording themselves presenting their posters. In this video, Dr. Marescotti focuses on systems toxicology assessment of a representative e-liquid formulation by using human primary bronchial epithelial cells.

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.